First patient dosed in ulcerative colitis drug trial
Drug Discovery World
MARCH 29, 2023
A Phase I clinical trial has begun evaluating Direct Biologics’ ExoFlo for the treatment of patients with medically refractory ulcerative colitis (UC). Direct Biologics uses extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (MSCs) to address multiple disease indications.
Let's personalize your content